Life Science & Medical
TILT Biotherapeutics is developing immunotherapies using a new type of genetically modified viruses. The company’s leading drug candidate, TILT-123, is an oncolytic virus derived from a common cold-causing adenovirus, which, based on current research results, may be helpful in treating solid tumors. Solid tumors, which are not blood cancers, account for over 90 percent of all cancer types.
Uniogen Oy. Health technology company Uniogen is developing next-generation diagnostic solutions for the detection of cancers and infectious diseases. The company aims to revolutionize early-stage cancer diagnostics by introducing a simple and accurate blood test to the market.
Desentum Oy. Desentum is a Finnish pharmaceutical development company (a spin-off from VTT) that is developing allergy immunotherapy using novel genetically modified allergens. The company’s goal is to improve the effectiveness and safety of allergy immunotherapy, as well as to make it faster and easier for patients.
Medicubex Oy. Medicubex has developed and introduced to the market, world’s first digital and fully automated self-measurement solution, Medicube X® e-Health Station™.
NewIcon Oy. NewIcon is a health technology company that develops, manufactures, and sells innovative automation systems for the storage, distribution, and dispensing of medications, along with related software, for global markets. In Finland, the company has over 400 installed systems in hospitals and pharmacies.
LS CancerDiag Oy. LS CancerDiag is a diagnostics company that has developed a breakthrough technology called DiagMMR for diagnosing Lynch syndrome, the most common hereditary cancer syndrome worldwide. The company’s unique technological innovation is the result of over ten years of academic research. With this innovation, individuals who have inherited the syndrome can be identified at an early stage and directed towards cancer-preventive monitoring.